首页> 外文期刊>Hereditary cancer in clinical practice >Update on the Cytogenetics and Molecular Genetics of Chordoma
【24h】

Update on the Cytogenetics and Molecular Genetics of Chordoma

机译:脊索瘤的细胞遗传学和分子遗传学研究进展

获取原文
           

摘要

Chordoma is a rare mesenchymal tumour of complex biology for which only histologic and immunohistochemical criteria have been defined, but no biomarkers predicting the clinical outcome and response to treatment have yet been recognised. We herein review the interdisciplinary information achieved by epidemiologists, neurosurgeons and basic scientists on chordoma, usually a sporadic tumour, which also includes a small fraction of familial cases. Main focus is on the current knowledge of the genetic alterations which might pinpoint candidate genes and molecular mechanisms shared by sporadic and familiar chordomas. Due to the scarcity of the investigated tumour specimens and the multiple chromosome abnormalities found in tumours with aberrant karyotypes, conventional cytogenetics and Fluorescence In Situ Hybridization failed to detect recurrent chordoma-specific chromosomal rearrangements. Genome-wide approaches such as Comparative Genomic Hybridization (CGH) are yet at an initial stage of application and should be implemented using BAC arrays either genome-wide or targeting selected genomic regions, disclosed by Loss of Heterozygosity (LOH) studies. An LOH region was shown by a systematic study on a consistent number of chordomas to encompass 1p36, a genomic interval where a candidate gene was suggested to reside. Despite the rarity of multiplex families with chordoma impaired linkage studies, a chordoma locus could be mapped to chromosome 7q33 by positive lod score in three independent families. The role in chordomagenesis of the Tuberous Sclerosis Complex (TSC) genes has been proved, but the extent of involvement of TSC1 and TSC2 oncosuppressors in chordoma remains to be assessed. In spite of the scarce knowledge on the genetics and molecular biology of chordoma, recent initiation of clinical trials using molecular-targeted therapy, should validate new molecular targets and predict the efficacy of a given therapy. Comparative genetic and biomolecular studies should enhance the molecular taxonomy of chordoma which might have a prognostic significance and better orient the therapeutic options.Keywords: chordoma, 1p36 LOH, 7q33 linkage, TSC association
机译:脊索瘤是一种罕见的复杂生物学的间充质肿瘤,仅定义了组织学和免疫组织化学标准,但尚无可预测临床结果和对治疗反应的生物标志物。我们在这里回顾了流行病学家,神经外科医生和基础科学家在脊索瘤(通常是散发性肿瘤)上获得的跨学科信息,其中脊索瘤还包括一小部分家族性病例。主要关注点是遗传改变的最新知识,这可能会查明散发性和熟悉的脊索瘤共有的候选基因和分子机制。由于所研究的肿瘤标本的稀缺性以及在核型异常的肿瘤中发现的多条染色体异常,常规细胞遗传学和荧光原位杂交未能检测到复发的脊索瘤特异性染色体重排。诸如比较基因组杂交(CGH)之类的全基因组方法尚处于初步应用阶段,应使用全基因组或针对选定基因组区域的BAC阵列来实施,这由杂合性缺失(LOH)研究披露。通过对一致数目的脊索瘤的系统研究显示,LOH区域涵盖了1p36,这是一个建议候选基因存在的基因组区间。尽管很少有多重家族与脊索瘤的连锁研究受损,但脊索瘤基因座可通过三个独立家族的阳性lod得分定位到染色体7q33。已经证明了结节性硬化复合物(TSC)基因在脊索瘤形成中的作用,但是TSC1和TSC2抑癌药在脊索瘤中的参与程度仍有待评估。尽管对脊索瘤的遗传学和分子生物学知识缺乏,但最近开始使用分子靶向疗法的临床试验仍应验证新的分子靶点并预测给定疗法的疗效。遗传和生物分子的比较研究应增强脊索瘤的分子分类学,这可能具有预后意义并更好地指导治疗选择。关键词:脊索瘤,1p36 LOH,7q33连锁,TSC关联

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号